To conduct and fund scientific research for cancer and various medical research projects and clinical studies.
Main program · fiscal year 2025
These revenues and expenses are associated with clinical trials funded by pharmaceutical companies, universities, device companies, and diagnostic testing laboratories. The information obtained by the organization from these clinical studies allows the organization to meet its charitable purposes of offering cutting edge diagnostic testing (to detect cancer as early as possible), creating new drug… Read more
These revenues and expenses are associated with clinical trials funded by pharmaceutical companies, universities, device companies, and diagnostic testing laboratories. The information obtained by the organization from these clinical studies allows the organization to meet its charitable purposes of offering cutting edge diagnostic testing (to detect cancer as early as possible), creating new drug treatment therapies, and creating molecular interventional strategies to prevent future relapses of cancer. The organization utilizes this information to advise and educate patients who are fighting cancer and other diseases.
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Operating reserves (reduced: more than 3 years of cash)
10+ yrs; 10+ yrs in cash
0 / 25
Financial balance (median margin)
+1220.9%
0 / 20
Transparency
4 full 990s, latest TY2025
20 / 20
Program growth
−69.5% / yr
0 / 15
Track record
12 years
4.8 / 10
Debt load
0.0% of assets
10 / 10
Total
34.8 → 35
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$172,904Fiscal year 2025
Expenses$6,774Fiscal year 2025
Total assets$1,260,040Fiscal year 2025
Total liabilities$48Fiscal year 2025
Fiscal year ending December2025
Revenue$172,904
Expenses$6,774
Net income$166,130
Net assets$1,259,992
Notable sources of revenue
Percent of total revenue
Contributions
$172,904
100.0%
Program services
$0
0.0%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$1,260,040
Total liabilities
$48
Net assets
$1,259,992
Compensation
Not in our extract for this year.
Fiscal year ending December2024
Revenue$183,281
Expenses$5,978
Net income$177,303
Net assets$1,093,861
Notable sources of revenue
Percent of total revenue
Contributions
$183,281
100.0%
Program services
$0
0.0%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$1,195,471
Total liabilities
$101,610
Net assets
$1,093,861
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$151,199
Expenses$302,509
Net income−$151,310
Net assets$916,558
Notable sources of revenue
Percent of total revenue
Contributions
$151,199
100.0%
Program services
$0
0.0%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$1,116,558
Total liabilities
$200,000
Net assets
$916,558
Compensation
Officers and key employees
$0
Share of expenses
0.0%
Fiscal year ending December2022
Revenue$213,380
Expenses$238,786
Net income−$25,406
Net assets$1,016,979
Notable sources of revenue
Percent of total revenue
Contributions
$213,380
100.0%
Program services
$0
0.0%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$1,171,633
Total liabilities
$154,654
Net assets
$1,016,979
Compensation
Officers and key employees
$0
Share of expenses
0.0%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?